Trials / Completed
CompletedNCT04154501
A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects
A Study to Evaluate the Safety and Pharmacokinetics of Single Doses of CNTX-6016 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Centrexion Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A Phase 1 double-blind, placebo-controlled, randomized single ascending dose incorporating an open-label, 2-period crossover, food effect cohort.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CNTX-6016 | Oral Dose CNTX-6016 |
| OTHER | Other: Placebo | Oral Dose Placebo |
Timeline
- Start date
- 2018-12-04
- Primary completion
- 2019-08-21
- Completion
- 2019-08-26
- First posted
- 2019-11-06
- Last updated
- 2019-11-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04154501. Inclusion in this directory is not an endorsement.